Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia


Acquired pure red cell aplasia is a rare condition characterized by normocytic normochromic anemia with severe reticulocytopenia. In refractory acquired pure red cell aplasia, the low response rate of immunosuppressive therapy also constitutes a challenge. We herein report the case of a 58-year-old male with refractory acquired pure red cell aplasia that was successfully treated by eltrombopag at a dose of 75 mg/day. After application of eltrombopag, the patient achieved complete remission and tolerated the treatment very well, with only mild bilirubin elevation. These preliminary findings showed that eltrombopag may be effective and well tolerated in adult patients with refractory acquired pure red cell aplasia.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2


  1. 1.

    Means RT Jr. Pure red cell aplasia. Blood. 2016;128(21):2504–9.

    CAS  Article  Google Scholar 

  2. 2.

    Xuemei Wu, Wang S, Xing-Yu Lu, Shen W, Qiao C, Yujie Wu, et al. Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. Int J Hematol. 2018;108:123–9.

    Article  Google Scholar 

  3. 3.

    Liu X, Xingyu Lu, Chen L, Xuemei Wu, Ruinan Lu, Wang S, et al. Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective. Ann Hematol. 2020;99(3):443–9.

    CAS  Article  Google Scholar 

  4. 4.

    Gill H, Wong RSM, Kwong YL. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Ther Adv Hematol. 2017;8(5):159–74.

    CAS  Article  Google Scholar 

  5. 5.

    Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.

    CAS  Article  Google Scholar 

  6. 6.

    Gill H, Leung GM, Lopes D, Kwong YL. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol. 2017;176(6):991–4.

    CAS  Article  Google Scholar 

  7. 7.

    Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.

    CAS  Article  Google Scholar 

  8. 8.

    Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86.

    CAS  Article  Google Scholar 

  9. 9.

    Alvarado LJ, Huntsman HD, Cheng H, Townsley DM, Winkler T, Feng XM, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019;133(19):2043–55.

    CAS  Article  Google Scholar 

  10. 10.

    Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212–20.

    CAS  Article  Google Scholar 

  11. 11.

    Huang Y, Jiang X, Han B. Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report. Ther Adv Hematol. 2020;11:2040620720940144.

    Article  Google Scholar 

  12. 12.

    Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, et al. Eltrombopag for the treatment of refractory pure RBC Aplasia after Major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:1765–70.

    CAS  Article  Google Scholar 

  13. 13.

    Dragani M, Andreani G, Familiari U, Marci V, Rege-Cambrin G. Pure red cell aplasia and amegakaryocytic thrombocytopenia in thymoma: the uncharted territory. Clin Case Rep. 2020;8:598–601.

    Article  Google Scholar 

  14. 14.

    Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833–43.

    CAS  Article  Google Scholar 

  15. 15.

    Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Hematol Am Soc Hematol Educ Program. 2018;2018:450–6.

    Article  Google Scholar 

  16. 16.

    Winkler T, Cooper JN, Townsley DM, Scheinberg P, Grasmeder S, Wu C, et al. Eltrombopag for refractory aplastic anemia: dosing regimens, long-term followup, clonal evolution and somatic mutation profiling. Blood. 2017;130(suppl 1):777.

    Google Scholar 

  17. 17.

    Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2(4):454–61.

    CAS  Article  Google Scholar 

Download references


This study was supported by State Administration of Traditional Chinese Medicine Industry Specialty (No.201407001-4), National Public Health Grand Research Foundation (No.201202017), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801), and Project Funded by Jiangsu Provincial Special Program of Medical Science (No. BL2014086).

Author information




All authors have made substantial intellectual contributions to this study. Guangsheng He performed study design and was involved in manuscript drafting and revision. Xiaoqing Liu collected and analyzed the data and drafted the manuscript. Lang Cheng, Yao He and Run Zhang collected and interpreted the data and helped write the manuscript. Ruinan Lu, Jianfu Zhang, Ming Hong and Jianyong Li revised the manuscript.

Corresponding author

Correspondence to Guangsheng He.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Cheng, L., He, Y. et al. Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia. Int J Hematol (2021). https://doi.org/10.1007/s12185-021-03100-2

Download citation


  • Pure red cell aplasia
  • Refractory
  • Immunosuppressive therapy
  • Eltrombopag
  • Erythropoiesis